Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Jaromir Tomasik
Observed name:
Tomasik, Jaromir
Institution:
Medical University of Warsaw
Observed institution:
Medical University of Warsaw
ORCID:
0000-0003-0255-3138
Observed ORCID:
0000-0003-0255-3138
OpenAlex ID:
A5085467706
Next generations of CAR-T cells - new therapeutic opportunities in hematology?
2022
·
Jaromir Tomasik
, Marcin Jasiński
, et al.
·
Frontiers in Immunology
·
187
Inflammasomes—New Contributors to Blood Diseases
2022
·
Jaromir Tomasik
, Grzegorz Władysław Basak
·
International Journal of Molecular Sciences
·
25
PDF
Endothelial Activation and Stress Index Score as a Prognostic Factor of Cytokine Release Syndrome in CAR-T Patients – A Retrospective Analysis of Multiple Myeloma and Large B-Cell Lymphoma Cohorts
2024
·
Jaromir Tomasik
, Batia Avni
, et al.
·
Archivum Immunologiae et Therapiae Experimentalis
·
11
PDF
Incorporating mRNA therapeutics into biological treatments of hematologic malignancies
2025
·
Jaromir Hunia
, Jaromir Tomasik
, et al.
·
Frontiers in Immunology
·
6
PDF
Meta-analysis of response rates to first-line salvage treatment after CAR-T therapy failure in large B-cell lymphoma patients
2024
·
Jaromir Tomasik
, Dominik Bilicki
, et al.
·
Expert Opinion on Biological Therapy
·
5
Second Primary Malignant Neoplasms After T-Cell–Engaging Bispecific Antibody Therapy: A Systematic Review and Meta-Analysis
2026
·
Jaromir Tomasik
, Tobias Tix
, et al.
·
JAMA Oncology
·
2
Hematotoxicity and immune deficits with bispecific antibodies: A systematic review and meta-analysis in lymphoma and multiple myeloma
2025
·
Tobias Tix
, Mohammad Alhomoud
, et al.
·
Blood
·
2
PDF
Tisagenlecleucel CAR-T for relapsed/refractory diffuse large B-cell lymphoma, one therapy; two different clinical presentations. An urgent need to design adverse event predictors
2023
·
Jaromir Tomasik
, Joanna Drozd-Sokołowska
, et al.
·
Acta Haematologica Polonica
·
2
PDF
Salvage Therapies After Anti‐BCMA CAR‐T Failure in Patients With Multiple Myeloma: A Meta‐Analysis of Response Rates
2026
·
Jaromir Tomasik
, Roni Shouval
, et al.
·
European Journal Of Haematology
·
1
PDF
The first integrated proteomic and lipidomic profiling reveals immune, metabolic, and membrane remodeling signatures in patients experiencing cytokine release storm (CRS) undergoing CAR-T cell therapy and serves as a new predictive and prognostic factor.
2025
·
Kannathasan Thetchinamoorthy
, Diana Wierzbicka
, et al.
·
Blood
·
1
Complementary Observations for Interpreting Findings of T-Cell–Engaging Bispecific Antibody Therapy—Reply
2026
·
Jaromir Tomasik
, Kai Rejeski
, et al.
·
JAMA Oncology
Unsupervised proteomic and metabolomic longitudinal serum profiling of anti-CD19 CAR-T cell therapy recipients reveals clinically distinct groups
2025
·
Jaromir Tomasik
, Kannathasan Thetchinamoorthy
, et al.
·
Blood
PDF
Meta-Analysis of Complete Remission Rates Following First-Line Salvage Treatment after Anti-CD19 CAR-T Failure in Adult Patients with Relapsed and Refractory B-Cell Acute Lymphoblastic Leukemia
2024
·
Jaromir Tomasik
, Dominik Bilicki
, et al.
·
Blood
Show more works
View as search
Works count:
14
Citation count:
242
H-index:
5
I10-index:
3
Year
Topic
Type